J&J's (JNJ) Janssen Receives FDA Panel Backing for MDR-TB Drug Bedaquiline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
J&J's (JNJ) Experimental TB Drug Receives Unanimous FDA Panel Backing
November 28, 2012 5:19 PM ESTJohnson & Johnson (NYSE: JNJ) got some good news late Wednesday after an FDA panel said it would back its experimental tuberculosis drug, bedaquiline.
The drug targets adenosine triphosphate synthase, which is an enzyme that TB needs to generate energy.
The... More
